Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBITDA (2020 - 2025)

Arcutis Biotherapeutics has reported EBITDA over the past 6 years, most recently at $17.4 million for Q4 2025.

  • For Q4 2025, EBITDA rose 253.72% year-over-year to $17.4 million; the TTM value through Dec 2025 reached -$16.2 million, up 88.45%, while the annual FY2025 figure was -$16.2 million, 88.45% up from the prior year.
  • EBITDA for Q4 2025 was $17.4 million at Arcutis Biotherapeutics, up from $7.4 million in the prior quarter.
  • Over five years, EBITDA peaked at $17.4 million in Q4 2025 and troughed at -$108.1 million in Q3 2022.
  • A 5-year average of -$46.8 million and a median of -$48.6 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: plummeted 110.14% in 2021 and later soared 253.72% in 2025.
  • Year by year, EBITDA stood at -$71.6 million in 2021, then rose by 0.08% to -$71.5 million in 2022, then increased by 7.57% to -$66.1 million in 2023, then soared by 82.86% to -$11.3 million in 2024, then soared by 253.72% to $17.4 million in 2025.
  • Business Quant data shows EBITDA for ARQT at $17.4 million in Q4 2025, $7.4 million in Q3 2025, and -$15.8 million in Q2 2025.